Kadmon start Phase 2 for KD025 in treatment of psoriasis

[Fred]

Called  Belimosudil now and being tested for other diseases.
 
Study results not posted on library site I found with studies/trials.

Confirmed:

Quote:

---

Belumosudil (KD025), is an orally administered, selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates immune and fibrotic processes. A pivotal study of belumosudil is ongoing in patients with chronic graft-versus-host disease (cGVHD), a complication following hematopoietic cell transplantation (HCT) that results in multi-organ inflammation and fibrosis.

A Phase 2 clinical trial of belumosudil is also underway in systemic sclerosis (SSc), a chronic immune disorder characterized by fibrosis of the skin and internal organs. ROCK mediates cell movement, shape, differentiation and function. Kadmon’s research has helped define the role of ROCK in the pathogenesis of many diseases, including immune and fibrotic diseases. Specifically, our research has demonstrated that belumosudil helps to resolve immune dysregulation by down-regulating pro-inflammatory Th17 cells and increasing regulatory T (Treg) cells.

No point posting results here as it's no longer a psoriasis or psoriatic arthritis related treatment but I will PM you.